BACKGROUND AND AIMS: Sera from cancer patients contain tumor-specific autoantibodies directly against antigenic proteins. The identification of tumor autoantigens may have utility in cancer diagnosis, prognosis, and therapy. In this study, we used immunoproteomics analysis to identify tumor proteins that elicit humoral response in colorectal cancer (CRC). MATERIALS AND METHODS: The CRC cell line HCT116 was used as a source of proteins for two-dimensional polyacrylamide gel electrophoresis and subsequent Western blot analysis in which individual serum from patients with CRC was analyzed for autoantibodies. Proteins that specifically react with sera from cancer patients were identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometric analysis. In addition, the selected protein expression in tumor tissues collected from 40 patients with CRC were assessed by immunohistochemistry. RESULTS: An autoantibody against inosine monophosphate dehydrogenase II (IMPDH2) identified by mass spectrometry was detected in eight out of 25 patients with CRC. However, none of the 15 healthy controls demonstrated autoantibody to IMPDH2.The expression of IMPDH2 in tumor tissue was significantly higher in patients with CRC than that in healthy subjects. CONCLUSIONS: The result confirmed that the immunoproteomics analysis holds considerable promise for the discovery of tumor-associated antigens. IMPDH2 may be a protein biomarker and novel therapeutic target in CRC.
BACKGROUND AND AIMS: Sera from cancerpatients contain tumor-specific autoantibodies directly against antigenic proteins. The identification of tumor autoantigens may have utility in cancer diagnosis, prognosis, and therapy. In this study, we used immunoproteomics analysis to identify tumor proteins that elicit humoral response in colorectal cancer (CRC). MATERIALS AND METHODS: The CRC cell line HCT116 was used as a source of proteins for two-dimensional polyacrylamide gel electrophoresis and subsequent Western blot analysis in which individual serum from patients with CRC was analyzed for autoantibodies. Proteins that specifically react with sera from cancerpatients were identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometric analysis. In addition, the selected protein expression in tumor tissues collected from 40 patients with CRC were assessed by immunohistochemistry. RESULTS: An autoantibody against inosine monophosphate dehydrogenase II (IMPDH2) identified by mass spectrometry was detected in eight out of 25 patients with CRC. However, none of the 15 healthy controls demonstrated autoantibody to IMPDH2.The expression of IMPDH2 in tumor tissue was significantly higher in patients with CRC than that in healthy subjects. CONCLUSIONS: The result confirmed that the immunoproteomics analysis holds considerable promise for the discovery of tumor-associated antigens. IMPDH2 may be a protein biomarker and novel therapeutic target in CRC.
Authors: Connie Brouwer; Diana G M Vermunt-de Koning; Robert C Trueworthy; Patricia G J H Ter Riet; John A Duley; Frans J M Trijbels; Peter M Hoogerbrugge; Jos P M Bökkerink; Elisabeth R van Wering; Ronney A De Abreu Journal: Pediatr Blood Cancer Date: 2006-04 Impact factor: 3.167
Authors: Su-Hyung Hong; David E Misek; Hong Wang; Eric Puravs; Thomas J Giordano; Joel K Greenson; Dean E Brenner; Diane M Simeone; Craig D Logsdon; Samir M Hanash Journal: Cancer Res Date: 2004-08-01 Impact factor: 12.701
Authors: Ying He; Zhousan Zheng; Yi Xu; Huiwen Weng; Ying Gao; Kai Qin; Jian Rong; Cui Chen; Miao Yun; Jiaxing Zhang; Sheng Ye Journal: Am J Cancer Res Date: 2018-08-01 Impact factor: 6.166
Authors: L Zhou; D Xia; J Zhu; Y Chen; G Chen; R Mo; Y Zeng; Q Dai; H He; Y Liang; F Jiang; W Zhong Journal: Clin Transl Oncol Date: 2014-03-22 Impact factor: 3.405
Authors: Johannes Söllner; Andreas Heinzel; Georg Summer; Raul Fechete; Laszlo Stipkovits; Susan Szathmary; Bernd Mayer Journal: Immunome Res Date: 2010-11-03
Authors: Alexander J Valvezan; Marc Turner; Amine Belaid; Hilaire C Lam; Spencer K Miller; Molly C McNamara; Christian Baglini; Benjamin E Housden; Norbert Perrimon; David J Kwiatkowski; John M Asara; Elizabeth P Henske; Brendan D Manning Journal: Cancer Cell Date: 2017-10-19 Impact factor: 31.743
Authors: Wendy C Carcamo; Minoru Satoh; Hideko Kasahara; Naohiro Terada; Takashi Hamazaki; Jason Y F Chan; Bing Yao; Stephanie Tamayo; Giovanni Covini; Carlos A von Mühlen; Edward K L Chan Journal: PLoS One Date: 2011-12-29 Impact factor: 3.240